Yamamoto H, et al. - This study was performed to elucidate the feasibility of monotherapy by rituximab without any additional desensitization treatments in ABO-incompatible living-donor liver transplantation (ABO-i LDLT). In this study, pretransplant rituximab without additional treatments resulted in satisfactory outcomes similar to that with additional treatments, such as plasmapheresis and local infusion.